uniQure N.V.

NASDAQ:QURE

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Investing News NetworkYour trusted source for investing success

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

13 Canadian Crypto ETFs (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

A State-by-State Guide to Cannabis in Australia (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

Can You Invest in Elon Musk’s Neuralink? (Updated 2024)

Top 4 Largest Lithium Reserves by Country (Updated 2024)

Investing in Graphene Companies (Updated 2024)

Radiopharm achieves Nasdaq listing of ADS

First Helium Reviewing Potential Follow Up Targets to Leduc Anomaly Drill

HyProMag USA Feasibility Study Demonstrates Robust Economics and the Opportunity to Develop a Major New, Domestic Source of Recycled Rare Earths Magnets for the United States

First Helium Confirms Plans for Sequential Drilling of Two Oil Targets - Proven Undeveloped Oil Location and Large Leduc Anomaly

CHARBONE Hydrogen Announces a First Closing of its $1M Non-Brokered Private Placement

Silver47 Drills 2.66 Metres of 1,801 g/t Silver Equivalent within 22.3 Metres of 601 g/t Silver Equivalent at its Red Mountain Project, Alaska

First Helium

Purpose Bitcoin ETF

Soma Gold Corp.

Black Swan Graphene

2024 Gold Outlook Report

2024 Graphite Outlook Report

2024 Lithium Market Outlook

2024 Uranium Outlook

uniQure N.V.

Interactive Chart